UnitedHealth rises 4.7% after quarterly results boost full-year outlook

What happened

UnitedHealth (UNH) rose 4.7% on October 14, 2026, because third-quarter results beat estimates and the company raised its full-year adjusted EPS outlook to at least $20.50. The company reported adjusted EPS of $4.69 against $4.14 expected, a 13.3% beat, and said consolidated revenue was about $112.7–$113 billion. Media coverage noted improving execution across UnitedHealthcare and Optum as a factor behind the results.

How big was the move

The stock closed at $395.62 after opening 1.2% above the previous close, with trading volume 1.4 times its 20-day average. The session's 4.7% gain was 3.4 times a typical daily move for this stock and outperformed the healthcare sector median by 5.6 percentage points while the S&P 500 fell 1.1% on the day. Over the last five sessions the stock rose 5.2%, while the S&P 500 fell 1.1% over the same period.

In the past five years the stock had 14 sessions with a gain of at least 4.7%. Twenty trading days after those sessions, the median result was a gain of 5.4%, and 11 of 14 were higher, underscoring that similar rallies often proved durable over that horizon.

The technical picture

The stock traded 5.3% above its 20-day moving average and 2.1% above its 50-day moving average, and it was 10.4% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 129 consecutive trading days above its 200-day average.

Momentum indicators showed a neutral short-term reading: the Relative Strength Index (14 days) was 62, between the typical 30-to-70 band. The shares remained 14.3% below the 52-week high. Volatility was 22% annualized over 60 days, which is lower than 73% of its own readings over five years, suggesting relatively subdued price swings recently for a stock of this size.

Fundamentals and valuation

On a trailing four-quarter basis through September 30, 2026, revenue was $449.66 billion, up 3.3% from a year earlier, and diluted earnings per share were $17.52, down 8.6%. Gross margin improved to 22.8% from 19.7% a year earlier, while operating margin was 5.3% versus 6.1% a year earlier. Free-cash-flow margin stood at 5.1%, return on invested capital was 9.2%, and the balance sheet showed net debt of 1.7 times EBITDA. The company reduced its share count by 1.1% over the past year.

The stock trades at 22.6 times trailing earnings and 20.0 times expected earnings, with a free-cash-flow yield of 6.6%. Its price-to-trailing-earnings ratio is lower than 71% of its own readings over the past five years; the five-year median is 26.3 times earnings. Those valuation metrics suggest the market is assigning a premium compared with many historical readings but below the company’s five-year median multiple.

PromtFinance scores rank UnitedHealth highly on value and stability, with Value at 95 (Exceptional) and Stability at 84 (Strong). Momentum and revisions are positive at 72 and 75 respectively, while Growth scores 37 (Weak), reflecting slower expected earnings expansion relative to peers.

Earnings and analyst expectations

UnitedHealth reported third-quarter 2026 adjusted EPS of $4.69, up from $2.92 a year earlier, and consolidated revenue of about $112.7–$113 billion, according to media coverage. The company said its consolidated medical care ratio improved to 88.4% from 89.9% year-over-year, with favorable reserve development contributing about 70 basis points. This marked the fifth consecutive quarter beating estimates; the average surprise over the last four reports was 13.4% above estimates.

Historically, the stock has tended to fall after earnings: the typical two-day reaction after recent reports had been a decline of 5.9%. This quarter’s positive reaction bucked that recent pattern. Analysts responded with a mix of reiterations and forecast adjustments; the consensus price target is $470.11 based on 52 analysts, 18.8% above the closing price, and 83% of analysts rate the stock Buy. The next scheduled earnings report is January 26, 2027.

What to watch

• January 26, 2027: next scheduled earnings report.
• The raised full-year 2026 adjusted EPS outlook to at least $20.50, as announced with the quarter.
• Commentary on core Medicaid margins and the company view that Medicaid is at or near a trough, with expectations of improvement after 2026.
• Consensus price target of $470.11, which is 18.8% above the closing price, based on 52 analysts and a consensus rating of Buy.
• Trading volume and short-term price action relative to its 20-day and 50-day averages following analyst revisions.